SCHEMBL644865

SCHEMBL644865

CC(=O)Oc1cc(C(=O)O)cc2sccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
TSHR P16473 3/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.53
RAB9A P51151 1/20 0.53
PKM P14618 3/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
TTR P02766 2/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 1/20 0.43
ABCC4 O15439 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
HSP90AA1 P07900 1/20 0.43
CHRM2 P08172 1/20 0.43
HSP90AB1 P08238 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742360 0.74 MAPK1 (0.44) KDM4ETSHRALDH1A1GAAPKM
SCHEMBL7004530 0.74 HTT (0.40) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL2643772 0.73 GCK (0.42) PTGS2
SCHEMBL4961779 0.72 ALDH1A1 (0.56) KDM4ETSHRALDH1A1GAARAB9A
SCHEMBL11053213 0.72 KDM4E (0.44) KDM4ETSHRALDH1A1GAARAB9A
SCHEMBL9902892 0.72 TSHR (0.47) KDM4ETSHRALDH1A1GAARAB9A
SCHEMBL8830887 0.71 KDM4E (0.63) KDM4ETSHRALDH1A1GAARAB9A
3,4,5-Triacetoxybenzoic Acid SCHEMBL716891 0.71 KDM4E (0.63) KDM4ETSHRALDH1A1GAARAB9A
Hydrochloric Acid SCHEMBL9780454 0.71 ALDH1A1 (0.54) KDM4ETSHRALDH1A1GAARAB9A
SCHEMBL10951979 0.71 MAPT (0.46) KDM4EALDH1A1GAARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds GCK, GCKR, HK1 KDM4E 1790/4885TSHR 730/4885ALDH1A1 1370/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 KDM4E 1790/4885TSHR 730/4885ALDH1A1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.